Please assess the completion status of the following clinical trial:

Trial Title: Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with confirmed symptomatic PE or proximal DVT of the leg(s) who have been treated for 6 to 18 months with therapeutic dosages (intended INR between 2-3) of an oral VKA (e.g. warfarin, acenocoumarol, phenprocoumon, or fluindione) or RE-COVER study medication up to the moment of screening for the current study.~2. Written informed consent~Exclusion criteria:~1. Younger then 18 years of age~2. Indication for VKA other than DVT and/or PE~3. Patients in whom anticoagulant treatment for their index PE or DVT should be continued~4. Active liver disease or liver disease decreasing survival (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or ALAT \> 3 x ULN~5. Creatinine clearance \< 30 ml/min~6. Acute bacterial endocarditis~7. Active bleeding or high risk for bleeding.~8. Uncontrolled hypertension (investigators judgement)~9. Intake of another experimental drug within the 30 days prior to randomization into the study~10. Life expectancy \<6 months~11. Childbearing potential without proper contraceptive measures\*, pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dabigatran etexilate 150 mg BID (Type: EXPERIMENTAL): Patient to receive dabigatran etexilatate capsules 150 mg twice daily
- matching placebo twice daily (BID) (Type: PLACEBO_COMPARATOR): Patient to receive dabigatran extexilate matching placebo capsules twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).